GSK Vaccines Deal History & Licensing Activity
GSK Vaccines is a large pharma headquartered in UK. Over the past three years, GSK Vaccines has been involved in 11 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals).
Deals (12mo)
4
Active Trials
30
Top Modality
Small Molecules
Focus Area
Codev Deals
GSK Vaccines Recent Deal Activity
Licensing, acquisition, and partnership transactions involving GSK Vaccines in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| neladalkib | GSK | Small Molecules | Phase 3 | acquisition | Jul 18, 2026 |
| STA-4783 | GSK | Small Molecules | Unknown | co development | Jul 17, 2026 |
| risvutatug rezetecan (ris-rez) / HS-20093 | GSK | ADC | Phase 3 | license |
GSK Vaccines Pipeline Focus
Therapeutic areas and modalities where GSK Vaccines is most active based on deal history and clinical trial data.
Therapeutic Areas
GSK Vaccines Strategic Signals
Key indicators of GSK Vaccines's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches GSK Vaccines's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Codev Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About GSK Vaccines Licensing & Deal Activity
GSK Vaccines is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 11 deals over the past three years, GSK Vaccines ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for GSK Vaccines include Codev Deals (5 deals and trials), Oncology (3 deals and trials), Mega Deals (2 deals and trials), and Metabolic (2 deals and trials). In terms of modality, GSK Vaccines has shown particular interest in small molecules, other, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for GSK Vaccines and 850+ other biopharma companies. Use our Solidus to benchmark your asset against GSK Vaccines's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.